Developments in Epidermal Growth Factor Receptor-Targeting Therapy for Solid Tumors: Focus on Matuzumab (EMD 72000)

REFERENCES

• Cohen S. Nobel lecture. epidermal growth factor. Biosci. Rep. 1986; 6(12)1017–1028
   PubMed Web of Science ®Google Scholar
• Masui H., Kawamoto T., Sato J. D., Wolf B., Sato G., Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984; 44(3)1002–1007
   PubMed Web of Science ®Google Scholar
• Masui H., Moroyama T., Mendelsohn J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res. 1986; 46(11)5592–5598
   PubMed Web of Science ®Google Scholar
• Mendelsohn J., Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 2003; 21(14)2787–2799
   PubMed Web of Science ®Google Scholar
• Baselga J. Why the epidermal growth factor receptor? the rationale for cancer therapy. Oncologist 2002; 7(Suppl. 4)2–8
   PubMed Web of Science ®Google Scholar
• Baselga J., Arteaga C. L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 2005; 23(11)2445–2459
   PubMed Web of Science ®Google Scholar
• Spano J. P., Lagorce C., Atlan D., Milano G., et al. Impact Of EGFR expression on colorectal cancer patient prognosis and survival. Ann. Oncol. 2005; 2005(16)1–102
   Google Scholar
• Resnick M. B., Routhier J., Konkin T., Sabo E., Pricolo V. E. Epidermal growth factor receptor, c-met, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin. Cancer Res. 2004; 10(9)3069–3075
   PubMed Web of Science ®Google Scholar
• Mckay J. A., Murray L. J., Curran S., Ross V. G., Clark C., Murray G. I., Cassidy J., Mcleod H. L. Evaluation of the epidermal growth factor receptor (egfr) in colorectal tumours and lymph node metastases. Eur. J. Cancer 2002; 38(17)2258–2264
   PubMed Web of Science ®Google Scholar
• Porebska I., Harlozinska A., Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000; 21(2)105–115
   PubMed Web of Science ®Google Scholar
• Giralt J., Eraso A., Armengol M., Rossello J., Majo J., et al. IEpidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2002; 2002(54)5–1460
   Google Scholar
• Torzewski M., Sarbia M., Verreet P., Bittinger F., Dutkowski P., Heep H., Willers R., Gabbert H. E. The prognostic significance of epidermal growth factor receptor expression in squamous cell carcinomas of the oesophagus. Anticancer Res 1997; 17(5B)3915–3919
   PubMed Web of Science ®Google Scholar
• Itakura Y., Sasano H., Shiga C., Furukawa Y., Shiga K., Mori S., Nagura H. Epidermal growth factor receptor overexpression in esophageal carcinoma an immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994; 74(3)795–804
   PubMed Web of Science ®Google Scholar
• Hanawa M., Suzuki S., Dobashi Y., Yamane T., Kono K., Enomoto N., Ooi A. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int. J. Cancer 2005; 118: 1173–1180
   Web of Science ®Google Scholar
• Yasui W., Sumiyoshi H., Hata J., Kameda T., Ochiai A., Ito H., Tahara E. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 1988; 48(1)137–141
   PubMed Web of Science ®Google Scholar
• Meert A. P., Martin B., Delmotte P., Berghmans T., Lafitte J. J., et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur. Respir. J. 2002; 2002(20)4–975
   Google Scholar
• Veale D., Ashcroft T., Marsh C., Gibson G. J., Harris A. L. Epidermal growth factor receptors in non-small cell lung cancer. Br. J. Cancer 1987; 55(5)513–516
   PubMed Web of Science ®Google Scholar
• Solbach C., Roller M., Ahr A., Loibl S., Nicoletti M., et al. Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer. Int. J. Cancer 2002; 2002(101)4–390
   Google Scholar
• Koenders P. G., Beex L. V., Geurts-Moespot A., Heuvel J. J., Kienhuis C. B., Benraad T. J. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res. 1991; 51(17)4544–4548
   PubMed Web of Science ®Google Scholar
• Toi M., Hamada Y., Nakamura T., Mukaida H., Suehiro S., et al. Immunocytochemical and biochemical analysis of epidermal growth factor receptor expression in human breast cancer tissues: relationship to estrogen receptor and lymphatic invasion. Int. J. Cancer 1989; 1989(43)2–220
   Google Scholar
• Wrba F., Reiner A., Ritzinger E., Holzner J. H., Reiner G. Expression of epidermal growth factor receptors (EGFR) on breast carcinomas in relation to growth fractions, estrogen receptor status and morphological criteria an immunohistochemical study. Pathol. Res. Pract. 1988; 183(1)25–29
   PubMed Web of Science ®Google Scholar
• Livasy C. A., Reading F. C., Moore D. T., Boggess J. F., Lininger R. A. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol. Oncol. 2006; 100: 101–106
   PubMed Web of Science ®Google Scholar
• Huang S. M., Harari P. M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs 1999; 17(3)259–269
   PubMed Web of Science ®Google Scholar
• Rusch V., Klimstra D., Venkatraman E., Pisters P. W., Langenfeld J., Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 1997; 3(4)515–522
   PubMed Web of Science ®Google Scholar
• Ching K. Z., Ramsey E., Pettigrew N., D'Cunha R., Jason M., Dodd J. G. Expression of Mrna for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol. Cell Biochem. 1993; 126(2)151–158
   PubMed Web of Science ®Google Scholar
• Untawale S., Zorbas M. A., Hodgson C. P., Coffey R. J., Gallick G. E., et al. Transforming growth factor-alpha production and autoinduction in a colorectal carcinoma cell line (Difi) with an amplified epidermal growth factor receptor gene. Cancer Res. 1993; 1993(53)7–1630
   Google Scholar
• Yoshida K., Kyo E., Tsuda T., Tsujino T., Ito M., Niimoto M., Tahara E. EGF and TGF-alpha, the ligands of hyperproduced egfr in human esophageal carcinoma cells, act as autocrine growth factors. Int. J. Cancer 1990; 45(1)131–135
   PubMed Web of Science ®Google Scholar
• Giralt J., De Las H. M., Cerezo L., Eraso A., Hermosilla E., et al. I The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother. Oncol. 2005; 2005(74)2–101
   Google Scholar
• Kopp R., Rothbauer E., Mueller E., Schildberg F. W., Jauch K. W., Pfeiffer A. reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels. Dis. Colon. Rectum. 2003; 46(10)1391–1399
   PubMed Web of Science ®Google Scholar
• Kopp R., Ruge M., Rothbauer E., Cramer C., Kraemling H. J., Wiebeck B., Schildberg F. W., Pfeiffer A. Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res 2002; 22(2B)1161–1167
   PubMed Web of Science ®Google Scholar
• Inada S., Koto T., Futami K., Arima S., Iwashita A. Evaluation Of malignancy and the prognosis of esophageal cancer based on an immunohistochemical study (P53, E-cadherin, epidermal growth factor receptor). Surg. Today 1999; 29(6)493–503
   PubMed Web of Science ®Google Scholar
• Mukaida H., Toi M., Hirai T., Yamashita Y., Toge T. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 1991; 68(1)142–148
   PubMed Web of Science ®Google Scholar
• Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004; 5(5)292–302
   PubMed Web of Science ®Google Scholar
• Sung M. W., Nagashima S., Johnson J. T., Van Dongen G. A., Whiteside T. L. The role of apoptosis in antibody-dependent cell-mediated cytotoxicity against monolayers of human squamous cell carcinoma of the head and neck targets. Cell Immunol. 1996; 171(1)20–29
   PubMed Web of Science ®Google Scholar
• Oshimi Y., Oshimi K., Miyazaki S. Necrosis and apoptosis associated with distinct ca2+ response patterns in target cells attacked by human natural killer cells. J. Physiol. 1996; 495: 319–329, Pt. 2
   PubMed Web of Science ®Google Scholar
• Kettleborough C. A., Saldanha J., Heath V. J., Morrison C. J., Bendig M. M. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng. 1991; 4(7)773–783
   PubMedGoogle Scholar
• Bier H., Hoffmann T., Haas I., Van L. A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol. Immunother. 1998; 46(3)167–173
   PubMed Web of Science ®Google Scholar
• Lo K-M, Lan Y, Zhang X, Wesolowski J, Brunkhorst B, Campbell I., Gillies S. The Role of ADCC Effector Function In The Anti-Tumor Activity Of Anti-EGFR antibodies in a mouse xenograft model. Clin. Cancer Res. 2003; 9(2)A124
   PubMedGoogle Scholar
• Burger A. M., Heiss N. S., Kreysch H. G., Schandelmaier K., Wirth G., Fiebig H. H., Grell M. The humanized monoclonal anti-EGFR antibody EMD72000 potently inhibits the growth of EGFR-expressing human tumor xenografts insensitive to chemotherapeutic drugs. Proc. Am. Assoc. Cancer Res. 2003; 44: 1139, Abstr. 5719
   Google Scholar
• Knecht R., Peters S., Adunka O., Strebhardt K., Gstoettner W., Hambek M. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents. Anticancer Res 2003; 23(3B)2577–2583
   PubMed Web of Science ®Google Scholar
• Amendt C., Mantell O., Peters M., Yezherlyev M., Jauch K.-W., Geissler E., Bruns C. J. In vivo activity of humanized monoclonal anti-EGFR antibody EMD 72000 in combination with gemcitabine on growth of primary pancreatic tumors and metastases in an orthotopic nude mouse model. Proc. Am. Assoc. Cancer Res. 2003; 44: 1434, Abstr. 6180
   Google Scholar
• Bier H., Hoffmann T., Hauser U., Wink M., Ochler M., Kovar A., Muser M., Knecht R. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother. Pharmacol. 2001; 47(6)519–524
   PubMed Web of Science ®Google Scholar
• Vanhoefer U., Tewes M., Rojo F., Dirsch O., Schleucher N., , Phase I, et al. study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 2004; 22(1)175–184
   PubMed Web of Science ®Google Scholar
• Trarbach T., Beyer T., Schleucher N., Stattaus J., Mueller S. P., et al. A Randomized Phase,I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers. J. Clin. Oncol. 2004; 22(14 Suppl)3018, Abstr. 3018 ASCO Meeting Abstracts
   Google Scholar
• Doi T., Ohtsu A., Saijo N., Takiuchi H., Ohhashi Y., et al. Phase I A study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” Administered Weekly In Japanese Patients With Advanced Solid Tumors; Safety, PK And PD results of skin biopsies. J. Clin. Oncol. 2005; 23(16 Suppl.)211s, Abstr. 3077Abstract No. 3077. ASCO Meeting Abstracts
   Web of Science ®Google Scholar
• Kollmannsberger C., Schittenhelm M., Honecker F., Tillner J., Weber D., Oechsle K., Kanz L., Bokemeyer C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (Matuzumab) in combination with paclitaxel in patients with egfr-positive advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 2006; 17: 1007–1013
   PubMed Web of Science ®Google Scholar
• Graeven U., Kremer B., Südhoff T h., Killing B., Rojo F., Weber D., Tillner J., Schmiegel W. A phase I study of the humanized Igg1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in patient with advanced pancreatic cancer. Br. J. Cancer 2006; 94: 1293–1299
   PubMed Web of Science ®Google Scholar
• Rao S., Starling N., Benson M., Massey A., Wotherspoon A., et al. Phase I study of the humanized epidermal growth factor receptor (egfr) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma. J. Clin. Oncol. 2005; 23(16 Suppl.)314s, Abstr. 4028ASCO Meeting Abstracts
   Web of Science ®Google Scholar
• Salazar R., Tabernero J., Rojo F., Jimenez E., Montaner I., et al. Dose-Dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (Mab) EMD 72000 administered every three weeks (Q3w). a phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). J. Clin. Oncol. 2005; 23: 127s, Abstr. 2002 ASCO Meeting Abstracts
   PubMedGoogle Scholar
• Tabernero J., Rojo F., Jimenez E., Montaner I., Santome L., et al. A phase I PK And serial tumor and skin pharmacodynamic (PD) study of weekly (Q1w), every 2-week (Q2w) or every 3-week (Q3w) 1-hour (H) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (Pt) with advanced tumors. 2003; 22: 192, Abstr. 770
   Google Scholar
• Tillner J., Golob M., Vanhoefer U., Tabernero J., Rosen O., Kovar A. Pharmacokinetics (PK) of the novel humanized anti-EGFR Mab EMD 72000. Clin. Cancer Res. 2003; 9(2)A110
   Google Scholar
• Trarbach T., Schleucher N., Weber D., Tillner J., Fassmann I., Seeber S., Vanhoefer U. Phase I. study of the humanized anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (Pts) with advanced esophago-gastric (EG) adenocarcinoma. J. Clin. Oncol. 2005; 23(16 Suppl.)230s, (Abstr. 3156)ASCO Meeting Abstracts
   PubMed Web of Science ®Google Scholar
• Blohmer J., Gore M., Kuemmel S., Verheijen R. H., Kimmig R., et al. Phase II study to determine response rate, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of treatment with the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 (matuzumab) in patients with recurrent cervical cancer. J. Clin. Oncol. 2005; 23(16 Suppl.)174s, (Abstr. 2534)ASCO Meeting Abstracts
   Web of Science ®Google Scholar
• Seiden M., Burris H. A., Matulonis U., Hall J., Armstrong D., et al. A phase II trial of EMD72000 (Matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced mullerian malignancies. Gynecol. Oncol. 2007; 104: 727–731
   PubMed Web of Science ®Google Scholar
• Baselga J., Pfister D., Cooper M. R., Cohen R., Burtness B., , Phase I, et al. studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 2000; 18(4)904–914
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 1997; 3(12)2703–2707
   PubMed Web of Science ®Google Scholar
• Raben D., Helfrich B., Chan D. C., Ciardiello F., Zhao L., et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin. Cancer Res. 2005; 11(2)795–805, Pt. 1
   PubMed Web of Science ®Google Scholar
• Herbst R. S., Langer C. J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol. 2002; 29(1)27–36, Suppl. 4
   PubMed Web of Science ®Google Scholar
• Saltz L. B., Meropol N. J., Loehrer P. J., Sr., Needle M. N., Kopit J., Mayer R. J. Phase I I. trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004; 22(7)1201–1208
   PubMed Web of Science ®Google Scholar
• Robert F., Blumenschein G., Herbst R. S., Fossella F. V., Tseng J., Saleh M. N., Needle M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J. Clin. Oncol. 2005; 23(36)9089–9096
   PubMed Web of Science ®Google Scholar
• Lenz H., Mayer R J., Gold P., Mirtsching B., Cohn A. L.P., et al. Activity Of Erbitux (cetuximab) in patients with colorectal cancer refractory to a fluoropyrimidine, irinotecan, and oxaliplatin. 2005, Proc. ASCO Gastro Intestinal Cancers Symp. (Abstr. 225)
   Google Scholar
• Vermorken J., Bourhis J., Trigo J., Kies M., Leon X., et al. Cetuximab (Erbitux) in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies. 23(16S)501S, (Abstr. 5505)ASCO Meeting Abstracts 2005
   Google Scholar
• Physicians' Desk Reference, 60th Ed. Thomson PDR, Montvale, NJ 2006; 937–940
   Google Scholar
• Thienelt C. D., Bunn P. A., Jr., Hanna N., Rosenberg A., Needle M. N., Long M. E., Gustafson D. L., Kelly K. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J. Clin. Oncol. 2005; 23(34)8786–8793
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C., Schittenhelm M. N., Honecker F., Tillner J., Weber D., Oechsle K., Kanz L., Bokemeyer C. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 2006; 17: 1007–1013
   PubMed Web of Science ®Google Scholar
• Yang X. D., Jia X. C., Corvalan J. R.F., Wang P., Davis C. G., Jakobovits A. eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant hemotherapy. Cancer Res. 1999; 59(6)1236–1243
   PubMed Web of Science ®Google Scholar
• Bush T., Freeman D., Ogbagabriel S., Belmontes B., Kozlosky C., Baher A., et al. Activity of panitumumab alone and in combination with chemotherapy against mutant epdermal growth factor receptor (egfr)-expressing non-small cell lung carcinoma (NSCLC) cell lines and xenografts. 2005; 141–142, AACR-NCI-EORTC Annual Meeting
   Google Scholar
• Crawford J., Sandler A. B., Hammond L. A., Schiller J., Belani C., et al. ABX-EGF In combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22(14 Suppl.)7083, Meeting Abstracts
   Google Scholar
• Rowinsky E. K., Schwartz G. H., Gollob J. A., Thompson J. A., Vogelzang N. J., et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 2004; 2004(22)15–3003
   Google Scholar
• Peeters M., Van Cutsem E., Siena S., Humblet Y., Hendlisz A., et al. A Phase 3, Multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (Mcrc). Presentation At: Annual Meeting Of The American Association For Cancer Research. April, 2006. Washington, DC, 1–5
   Google Scholar
• Hecht J. R., Mitchell E., Baranda J., Malik I., Richards D., Navale L., D'Avirro P., Amado R. Panitumumab Antitumor Activity In Patients (pts) with metastatic colorectal cancer (Mcrc) expressing low (1–9%) Or Negative (.1%) levels of epidermal growth factor receptor (EGFR). Poster Presented At: Annual Meeting Of The American Society Of Clinical Oncology. June. Atlanta, GA 2006; 2–6
   Google Scholar
• Berlin J., Neubauer M., Swanson P., Harker W. G., Burris H., Hecht J. R., Navale L., Brown J., Amado R. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (Mcrc) Expressing > / = 10% epidermal growth factor receptor (EGFR). Poster Presented At: Annual Meeting Of The American Society Of Clinical Oncology. June. Atlanta, GA 2006; 2–6
   Google Scholar
• Weiner L. M., Belldegrun A., Rowinsky E., Crawford J., Lockbaum P., et al. Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies. J Clin Oncol 2005; 23(16 Suppl.)3059, Abstract Meeting Abstracts
   Google Scholar
• Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004; 2004(351)4–337
   Google Scholar
• Bonner J. A., Harari P. M., Giralt J., Azarnia N., Cohen R. B., et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. J. Clin. Oncol. 2004; 22(14 Suppl.)489s, Abstr. 5507
   Web of Science ®Google Scholar
• Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., Canon J. L., Van Laethem J. L., Maurel J., Richardson G., Wolf M., Amado R G. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 2007; 25: 1658–1664
   PubMed Web of Science ®Google Scholar
• Arends R., Yang B. B., Schwab G., Lockbaum P., Funelas C., Roskos L. Flexible dosing schedules of panitumumab (ABX-EGF) in cancer patients. J Clin Oncol 2005; 23(16 Suppl.)3089, Meeting Abstracts
   Google Scholar
• Hecht J. R., Patnaik A., Malik I., Venook A., Berlin J., et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (Mcrc): an updated analysis. J. Clin. Oncol. 2004; 22(14 Suppl.)3511, Meeting Abstracts
   Google Scholar
• Sunada H., Magun B. E., Mendelsohn J., Macleod C. L. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl. Acad. Sci. USA 1986; 83(11)3825–3829
   PubMed Web of Science ®Google Scholar
• Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [Corrected]. J. Clin. Oncol. 2003; 2003(21)12–2237
   Google Scholar
• Kris M. G., Natale R. B., Herbst R. S., Lynch T. J., Jr., Prager D., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A Randomized Trial. JAMA 2003; 2003(290)16–2149
   Google Scholar
• Lynch T. J., Bell D. W., Sordella R., Gurubhagavatula S., Okimoto R. A., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 2004(350)21–2129
   Google Scholar
• Paez J. G., Janne P. A., Lee J. C., Tracy S., Greulich H., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 2004(304)5676–1497
   Google Scholar
• Bell D. W., Lynch T. J., Haserlat S. M., Harris P. L., Okimoto R. A., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 2005; 2005(23)31–8081
   Google Scholar
• Cappuzzo F., Hirsch F. R., Rossi E., Bartolini S., Ceresoli G. L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 2005; 2005(97)9–643
   Google Scholar
• Shepherd F. A., Pereira J., Ciuleanu T. E., Tan E. H., Hirsh V., et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. a National Cancer Institute Of Canada Clinical Trials Group (NCIC CTG) trial. J. Clin. Oncol. 2004; 22(14_Suppl.)7022, Meeting Abstracts
   Google Scholar
• Tsao M. S., Sakurada A., Cutz J. C., Zhu C. Q., Kamel-Reid S., et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N. Engl. J. Med. 2005; 353(2)133–144
   PubMed Web of Science ®Google Scholar
• Hirsch F. R., Bunn P. A., Jr. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?. J. Clin. Oncol. 2005; 23(36)9044–9047
   PubMed Web of Science ®Google Scholar
• Shepherd F. A., Rodrigues P. J., Ciuleanu T., Tan E. H., Hirsh V., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005; 2005(353)2–123
   Google Scholar
• Perez-Soler R., Chachoua A., Hammond L. A., Rowinsky E. K., Huberman M., et al. Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer. J. Clin. Oncol. 2004; 2004(22)16–3238
   Google Scholar
• Hirsch F. R., Varella-Garcia M., Bunn P. A., Jr., Di Maria M. V., Veve R., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 2003; 21(20)3798–3807
   PubMed Web of Science ®Google Scholar
• Cappuzzo F., Hirsch F. R., Rossi E., Bartolini S., Ceresoli G. L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 2005; 2005(97)9–643
   Google Scholar
• Hirsch F. R., Varella-Garcia M., Mccoy J., West H., Xavier A. C., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J. Clin. Oncol. 2005; 2005(23)28–6838
   Google Scholar
• Cappuzzo F., Toschi L., Trisolini R., Bemis M., Sujita M., et al. Clinical and biological effects of gefitinib in EGFR FISH positive/phospho-akt positive or never smoker non-small cell lung cancer (NSCLC): preliminary results of the ONCOBELL trial. ASCO Meeting Abstracts 24. 2006, Abstract 7023
   Google Scholar
• Giaccone G., Herbst R. S., Manegold C., Scagliotti G., Rosell R., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1. J. Clin. Oncol. 2004; 2004(22)5–777
   Google Scholar
• Herbst R. S., Giaccone G., Schiller J. H., Natale R. B., Miller V., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2. J. Clin. Oncol. 2004; 2004(22)5–785
   Google Scholar
• Herbst R. S., Prager D., Hermann R., Miller V., Fehrenbacher L., et al. TRIBUTE - A Phase III trial of erlotinib hcl (OSI-774) Combined With Carboplatin And Paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2004; 22(14 Suppl.)7011, Meeting Abstracts
   Google Scholar
• Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22(14 Suppl.)7010, Meeting Abstracts
   Google Scholar
• Busam K. J., Capodieci P., Motzer R., Kiehn T., Phelan D., Halpern A. C. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br. J. Dermatol. 2001; 144(6)1169–1176
   PubMed Web of Science ®Google Scholar
• Van D. R., Kirtschig G., Scheffer E., Stoof T. J., Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br. J. Dermatol. 2002; 147(3)598–601
   PubMed Web of Science ®Google Scholar
• Perez-Soler R., Saltz L. Cutaneous Adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J. Clin. Oncol. 2005; 23(22)5235–5246
   PubMed Web of Science ®Google Scholar
• Burtness B., Goldwasser M. A., Flood W., Mattar B., Forastiere A. A. Phase I II. randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 2005; 23(34)8646–8654
   PubMed Web of Science ®Google Scholar
• Mita A. C., De Jonge M., Verweij J., Papadopoulos P., Schwartz G. K., et al. Erlotinib (Tarceva) dosing-to-rash: preliminary results of a pilot phase ii intra-patient dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) study of E in previously treated patients with advanced non-small cell lung cancer (NSCLC). AACR-NCI-EORTC International Conference—Molecular Targets and Cancer Therapeutics. Clin. Cancer Res. 2005; 11(24)9061s, Abstr. B118 Part 2.2005 156
   Web of Science ®Google Scholar